Carpenter-Coustan Compared With National Diabetes Data Group Criteria for Diagnosing Gestational Diabetes by Harper, Lorie M. et al.
Carpenter-Coustan Compared With National Diabetes Data 
Group Criteria for Diagnosing Gestational Diabetes
Lorie M. Harper, M.D., MSCI,
Departments of Obstetrics and Gynecology of The University of Alabama at Birmingham, 
Birmingham, AL
Lisa Mele, Sc.M.,
the George Washington University Biostatistics Center, Washington, DC
Mark B. Landon, M.D.,
The Ohio State University, Columbus, OH
Marshall W. Carpenter, M.D.,
Brown University, Providence, RI
Susan M. Ramin, M.D.,
The University of Texas Health Science Center at Houston-Children’s Memorial Hermann 
Hospital, Houston, TX
Uma M. Reddy, M.D., M.P.H.,
the Eunice Kennedy Shriver National Institute of Child Health and Human Development, 
Bethesda, MD
Brian Casey, M.D.,
University of Texas Southwestern Medical Center, Dallas, TX
Ronald J. Wapner, M.D.,
Columbia University, New York, NY
Michael W. Varner, M.D.,
University of Utah, Salt Lake City, UT
John M. Thorp Jr., M.D.,
University of North Carolina at Chapel Hill, Chapel Hill, NC
Anthony Sciscione, D.O.,
Drexel University, Philadelphia, PA
Patrick Catalano, M.D.,
Case Western Reserve University-MetroHealth Medical Center, Cleveland, OH
Corresponding Author: Lorie M. Harper, The University of Alabama at Birmingham, Department of Obstetrics and Gynecology, 
Address: 1700 6th Ave South, Ste 10270, Birmingham, AL 35233, Phone: 205-975-0515, Fax: 205-975-4375, lmharper@uabmc.edu.
*For a list of other members of the NICHD MFMU, see Appendix 1 online at http://links.lww.com/xxx.
Presented in part at the 35th Annual Meeting of the Society for Maternal-Fetal Medicine in San Diego, CA on February 6, 2015.
Financial Disclosure
The authors did not report any potential conflicts of interest.
HHS Public Access
Author manuscript
Obstet Gynecol. Author manuscript; available in PMC 2017 May 01.
Published in final edited form as:
Obstet Gynecol. 2016 May ; 127(5): 893–898. doi:10.1097/AOG.0000000000001383.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Margaret Harper, M.D., M.Sc.,
Wake Forest University Health Sciences, Winston-Salem, NC
George Saade, M.D.,
University of Texas Medical Branch, Galveston, TX
Steve N. Caritis, M.D.,
University of Pittsburgh, Pittsburgh, PA
Yoram Sorokin, M.D.,
Wayne State University, Detroit, MI
Alan M. Peaceman, M.D., and
Northwestern University, Chicago, IL
Jorge E. Tolosa, M.D., M.S.C.E.
Oregon Health & Science University, Portland, OR
for the Eunice Kennedy Shriver National Institute of Child Health and Human Development 
(NICHD) Maternal-Fetal Medicine Units (MFMU) Network*
Abstract
Objective—Use of Carpenter-Coustan compared to National Diabetes Data Group (NDDG) 
criteria increases the number of women diagnosed with GDM by 30-50%, but whether treatment 
of this milder GDM reduces adverse outcomes is unknown. We explored the effects of the 
diagnostic criteria used on the benefits of GDM treatment.
Methods—This was a secondary analysis of a randomized trial for treatment of mild GDM 
diagnosed using Carpenter-Coustan criteria. We evaluated the effect of treatment within two 
mutually exclusive diagnostic groups: 1) women who met the stricter NDDG as well as Carpenter-
Coustan criteria (NDDG) and 2) those diagnosed by Carpenter-Coustan but not meeting NDDG 
criteria (Carpenter-Coustan only). Maternal outcomes examined were pregnancy-induced 
hypertension, shoulder dystocia, maternal weight gain, and cesarean delivery. Neonatal outcomes 
were large for gestational age, macrosomia (>4000 g), fat mass, small for gestational age, and a 
composite outcome of perinatal death, birth injury, hypoglycemia, hyperbilirubinemia, and 
hyperinsulinemia. Analysis of variance or the Breslow Day test, as appropriate, was used to test 
for the interaction between diagnostic criteria and GDM treatment on the outcomes of interest.
Results—Of 958 patients, 560 (58.5%) met NDDG criteria and 398 (41.5%) met Carpenter-
Coustan only. Compared to untreated women, the direction of treatment effect did not differ by 
diagnostic criteria used and was consistent with the original trial. The p-value for interaction 
between diagnostic criteria and treatment status was not significant for any outcome.
Conclusion—The overall beneficial treatment effect on PIH, shoulder dystocia, cesarean 
delivery, and macrosomia was seen in patients diagnosed by the higher NDDG and by the lower 
thresholds of the Carpenter-Coustan criteria.
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Introduction
Perinatal outcomes are linked to maternal glycemia in a continuous fashion; no distinct 
threshold exists above which the risk of adverse outcomes dramatically increases as 
compared to below.(1-3) As a result, the diagnostic criteria for diagnosing gestational 
diabetes mellitus (GDM) are intensely debated. For example, positive cutoffs for the 3-hour 
glucose tolerance test may be the Carpenter-Coustan criteria or the more stringent National 
Diabetes Data Group (NDDG) criteria (Table 1). Although both the American College of 
Obstetricians and Gynecologists and an NIH consensus statement endorse two-step GDM 
screening with a 1-hour glucose challenge test followed by a fasting 3-hour glucose 
tolerance test, neither institute endorses specific criteria (Carpenter-Coustan or NDDG) for 
GDM diagnosis.(4, 5)
One reason that no diagnostic criteria are recommended over the other is the lack of data 
comparing the two. Several prior retrospective studies have demonstrated that women 
meeting the Carpenter-Coustan criteria for GDM had worse perinatal outcomes (increased 
odds of operative delivery, shoulder dystocia, LGA, macrosomia, or preeclampsia) compared 
to women not diagnosed with gestational diabetes.(6-9) In these studies, the Carpenter-
Coustan group was not treated for GDM; therefore, none can demonstrate that treatment at 
the Carpenter-Coustan level is effective at reducing these outcomes. However, compared to 
NDDG criteria, use of the less strict Carpenter-Coustan criteria would increase the number 
of women diagnosed with GDM by 30-50%.(10, 11)
We therefore explored the effects of the diagnostic criteria used for GDM diagnosis on the 
benefits of GDM treatment.
Materials and Methods
This was a secondary analysis of the Eunice Kennedy Shriver National Institute of Child 
Health and Human Development Maternal-Fetal Medicine Units Network randomized 
clinical trial for the treatment of mild GDM.(12). In the primary study, women between 24 
weeks 0 days and 30 weeks 6 days gestation with a 1-hour glucose challenge test between 
135 and 200 mg/dL underwent a 3-hour glucose tolerance test. Women were excluded if 
they had pre-existing diabetes, prior GDM, history of stillbirth, multifetal gestation, asthma, 
chronic hypertension, fetal anomaly, or were taking corticosteroids. Mild GDM was defined 
by a fasting glucose less than 95 mg/dL and at least two glucose values exceeding the 
Carpenter-Coustan thresholds. Women meeting criteria for mild GDM were randomized to 
usual care or treatment for GDM, which included nutritional counseling, diet therapy, and 
insulin if needed. The study was approved by the institutional review boards of all 
participating clinical centers, and all enrolled women gave written informed consent. Details 
of the protocol are available elsewhere, a brief description of management of gestational 
diabetes follows.(12)
Patients randomized to the treatment group received dietary counseling according to the 
2008 position statement of the American Diabetes Association within one week of 
enrollment. Women in the treatment group were instructed to take blood sugars fasting and 
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2-hours post-prandial with goals of <95 mg/dL fasting and <120 mg/dL post-prandial. 
Insulin therapy was reserved for patients with ≥50% of fasting or post-prandial levels 
elevated. In the control group, treatment was initiated at the discretion of the patient’s 
provider for random blood glucose ≥160 mg/dL or fasting ≥95 mg/dL.
For this analysis, two mutually exclusive groups were considered, 1) women with mild 
GDM meeting the NDDG criteria, 2) women with mild GDM meeting Carpenter-Coustan 
criteria but not NDDG criteria (Table 1). Within each of these two mutually exclusive 
exposure groups, women either received usual care or were treated for GDM, according to 
the randomization scheme used in the initial trial.
We selected outcomes from the primary study for which treatment of mild GDM was 
beneficial. In the primary study, treatment of mild GDM reduced the risk of pregnancy-
induced hypertension (PIH, defined as a systolic blood pressure of 140 mm Hg or more or a 
diastolic blood pressure of 90 mm Hg or more on two occasions at least 4 hours apart or one 
elevated blood pressure treated with medication), cesarean delivery, shoulder dystocia, large 
for gestational age infants (LGA, defined as birth weight greater than the 90th percentile of a 
U.S. reference population),(13) and macrosomia (defined as birth weight greater than 4000 
g). Treatment of mild GDM also reduced maternal gestational weight gain and neonatal fat 
mass. We therefore examined these outcomes in this secondary analysis. Although in the 
original study treatment did not demonstrate a reduction in the incidence of the primary 
outcome compared to usual care, we also compared the incidence of the original study’s 
primary outcome between groups. The primary outcome of the original study was a 
composite of perinatal death, neonatal hypoglycemia (glucose <35mg/dL within 2 hours of 
birth), neonatal hyperbilirubinemia (serum bilirubin >95th percentile between 16-36 hours 
after birth), neonatal hyperinsulinemia (cord blood C-peptide>95th percentile), and birth 
trauma (brachial plexus palsy, clavicular fracture, humeral fracture, or skull fracture). Of 
note, no perinatal deaths occurred in the cohort. Additionally, we assessed the incidence of 
small for gestational age infants (SGA, defined as birth weight less than the 10th percentile 
of a U.S. reference population).(13) Trained study personnel collected antepartum, 
intrapartum, and postdelivery data for enrolled women and their newborns at the time of 
discharge from the hospital. All cases of hypertensive disorders and shoulder dystocia 
underwent masked central review by two reviewers to ensure accurate diagnosis. Baseline 
characteristics of those diagnosed by NDDG and those diagnosed by Carpenter-Coustan 
were compared using the chi-square test for categorical variables and the Wilcoxon rank 
sum test for continuous variables. The analysis of variance or the Breslow-Day test for 
homogeneity, as appropriate, was used to test for interaction between the diagnostic criteria 
used and GDM treatment on the outcomes of interest. We then calculated the number needed 
to treat to prevent each of the outcomes for the overall group, the NDDG group, and the 
Carpenter-Coustan group. No adjustments were made for multiple comparisons. Statistical 
analyses were conducted using SAS software (SAS Institute, Cary, NC).
Results
Of 958 women diagnosed with GDM in the primary study, 560 (58.5%) met NDDG criteria 
and 398 (41.5%) met Carpenter-Coustan criteria only. Baseline characteristics were similar 
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between groups except for alcohol use and expected differences in blood glucose values on 
both the 50-g screening and 100-g diagnostic tests (Table 2). Of these 958 women, 931 
(97.2%) had outcomes data available and were included in further analysis.
Of 542 women meeting NDDG criteria with outcomes data available, 280 (51.7%) were 
randomized to treatment. Of 389 women with outcomes data meeting Carpenter-Coustan 
criteria alone, 196 (50.4%) were randomized to treatment. Maternal outcomes by diagnostic 
criteria and treatment status are shown in Table 3 (see Appendix 2, available online at http://
links.lww.com/xxx). The direction of treatment effect is consistent with the original trial, 
regardless of diagnostic criteria. The p-value for interaction was not significant for any 
maternal outcomes, demonstrating that treatment benefit did not vary by the diagnostic 
criteria met.
Neonatal outcomes by diagnostic criteria and treatment status are summarized in Table 4 
(see Appendix 3, available online at http://links.lww.com/xxx). Again, the direction of 
treatment effect was consistent with the original trial in both diagnostic criteria categories. 
The p-value for interaction was not significant for any neonatal outcomes, suggesting that 
those diagnosed by Carpenter-Coustan criteria benefit equally from treatment compared with 
those diagnosed by the stricter NDDG criteria.
The number needed to treat to prevent a single outcome of cesarean delivery, pregnancy-
induced hypertension, shoulder dystocia, LGA, and macrosomia were calculated for all 
GDM, NDDG criteria, and Carpenter-Coustan criteria (Table 5). With the exception of 
shoulder dystocia, the numbers needed to treat are small (20 or less for the overall group) 
and are similar between NDDG and Carpenter-Coustan criteria. A number needed to treat 
was not calculated for the composite neonatal outcome, as this was not reduced by treatment 
in the original study.
Discussion
The overall beneficial effect of treating GDM did not vary by the diagnostic criteria used. 
Women benefited from treatment even at the lower thresholds of the Carpenter-Coustan 
criteria. Additionally, with the exception of shoulder dystocia, the numbers needed to treat to 
prevent one adverse outcome are small, even in the Carpenter-Coustan group. The NIH 
consensus panel stated that a single standard for screening and diagnosis of GDM should be 
adopted by the appropriate professional organizations.(5) However, in the most recent 
practice bulletin, ACOG refrained from favoring one set of diagnostic criteria over the other 
due to lack of comparative trials.(4)
Several cohorts have been used to investigate outcomes in GDM diagnosed by NDDG and 
Carpenter-Coustan criteria. Cheng et al demonstrated that untreated GDM diagnosed by 
Carpenter-Coustan had higher risks of operative delivery, cesarean delivery, macrosomia, 
and shoulder dystocia compared to glucose-tolerant women.(8) In a large prospective cohort 
in Spain, women with untreated GDM diagnosed by Carpenter-Coustan criteria had 
increased risks of PIH and LGA infants compared to glucose-tolerant women.(6) Berggren 
et al compared outcomes in women with untreated GDM diagnosed by Carpenter-Coustan to 
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those with treated GDM diagnosed by NDDG criteria; untreated GDM diagnosed by the less 
stringent criteria was associated with increased risks of PIH and similar risks of cesarean, 
operative delivery, macrosomia, and shoulder dystocia.(7) Landon et al demonstrated that 
the risk of LGA and hypertensive disorders increased with values on the glucose tolerance 
test below the Carpenter-Coustan levels (1-hour value on the glucose tolerance test of 
165-179 mg/dL); however, only untreated women were included in this analysis.(3)
We identified one study in which women diagnosed with GDM by Carpenter-Coustan 
criteria alone were treated and compared to women with normal glucose tolerance.(10) In 
this study, women diagnosed and treated by the Carpenter-Coustan criteria alone had an 
increased risk of macrosomia compared to women with normal glucose tolerance. 
Unfortunately, only 16 women in this study met the definition of GDM by Carpenter-
Coustan criteria but not NDDG criteria; consequently, no comparisons were made to women 
with GDM by NDDG criteria.
While these studies consistently demonstrate increased risks of adverse outcomes in GDM 
diagnosed by Carpenter-Coustan criteria, none of them had a sufficient cohort of women 
treated at this level of glycemia to demonstrate treatment benefit. Our cohort is unique in 
that we had both treated and untreated women meeting both sets of diagnostic criteria, 
providing evidence that even at the lower glycemic thresholds of the Carpenter-Coustan 
criteria women can benefit from treatment.
Stratifying the cohort into two sets of diagnostic criteria naturally limited the power to detect 
a difference in outcomes between treated and untreated women in each diagnostic group. 
Despite the smaller numbers when comparing treated versus untreated within each 
diagnostic criteria category, the direction of treatment effect remained consistent with the 
original trial and no interaction between diagnostic criteria used and treatment effect was 
detected, indicating that both groups benefit equally from treatment. In addition, the 
estimates of outcomes for the two groups are fairly similar with overlapping 95% confidence 
intervals (available in Supplementary Material), suggesting that the non-significant p-values 
for interaction are not due to a lack of statistical power but are rather an indication that 
treatment benefits those diagnosed by both sets of criteria, although lack of statistical power 
cannot be completely ruled out.
In sum, women diagnosed with mild GDM by the less stringent Carpenter-Coustan criteria 
and by the stricter National Diabetes Data Group criteria both benefit from nutritional 
counseling, dietary therapy, and insulin when indicated.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Table 1
Diagnostic criteria for 3-hour glucose tolerance test.
Time of Testing Carpenter-Coustan National Diabetes Data Group
Fasting 95 105
1-Hour 180 190
2-Hour 155 165
3-Hour 140 145
At least 2 levels must be greater than or equal to the thresholds listed. All thresholds presented as mg/dL.
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Table 2
Study population characteristics.
Characteristic NDDG(n=560)
Carpenter-Coustan Only
(n=398) P-value
Age (yr) 29.3 ± 5.6 28.7 ± 5.7 0.19
Nulliparous 174 (31.1%) 132 (33.2%) 0.49
Race
0.48
 African American 63 (11.3%) 47 (11.8%)
 Caucasian 135 (24.1%) 107 (26.9%)
 Hispanic 322 (57.5%) 224 (56.3%)
 Other 40 (7.1%) 20 (5.0%)
Smoking 41 (7.3%) 28 (7.0%) 0.87
Alcohol use 13 (2.3%) 21 (5.3%) 0.01
BMI at entry (k/m2) 30.1 ± 5.1 30.2 ± 5.1 0.84
Gestational age at randomization (weeks) 28.8 ± 1.5 28.9 ± 1.5 0.16
50 gm screening value (mg/dl) 161.3 ± 15.9 156.7 ± 14.3 <0.001
3 hour OGTT values
 Fasting (mg/dl) 87.0 ± 5.5 85.7 ± 5.9 <0.001
 1 hour (mg/dl) 198.6 ± 21.1 184.1 ± 16.9 <0.001
 2 hour (mg/dl) 181.6 ± 20.4 162.0 ± 14.9 <0.001
 3 hour (mg/dl) 142.2 ± 30.6 126.6 ± 27.3 <0.001
OGTT: Oral glucose tolerance test. NDDG: National Diabetes Data Group.
Data are mean ± standard deviation or as n (%), unless otherwise specified.
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Table 5
Number Needed to Treat
Outcome All GDM NDDG Carpenter Coustan Only
Cesarean Delivery 14 44 7
Gestational Hypertension/Preeclampsia 20 23 17
Shoulder Dystocia 40 25 187
LGA 14 10 23
Macrosomia 12 10 16
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